ArticleScientific reports2025

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer.

Jiahao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.